InvestorSoup.com announces investment report featuring Exact Sciences

InvestorSoup.com announces an investment report featuring Exact Sciences Corp. (Nasdaq:EXAS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.investorsoup.com/lp/EXAS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Exact Sciences Corp. (EXAS) develops deoxyribonucleic acid (DNA)-based technologies for use in the detection of cancer. The Company has selected colorectal cancer as the first application of its technologies. The Company has licensed certain of its technologies, on an exclusive basis through December 2010, to Laboratory Corporation of America Holdings (LabCorp). LabCorp developed and commercially offered PreGen-Plus, its first generation non-invasive stool-based DNA colorectal cancer screening service for the average-risk population.

Message Board Search for EXAS: http://www.boardcentral.com/boards/EXAS

In the report, the analyst notes:

"EXAS reported total revenues of $1.2 million for the fourth quarter of 2009, compared to total revenues of ($109,000) during the same period of 2008. Fourth-quarter 2009 total revenues increased due to the quarterly non-cash allocation that resulted from a 2009 intellectual property license transaction. Total revenues for the year ended Dec. 31, 2009, were $4.8 million, compared to total revenues of ($867,000) for the prior year.

"By simplifying the routine screening process, stool-based DNA screening directly addresses patient non-compliance issues. As a result, more patients may be safely screened without the discomfort and inconvenience associated with invasive procedures. Greater compliance, in turn, may lead to earlier detection and potentially the prevention of colorectal cancer. Colorectal cancer is the second-leading cause of cancer deaths, according to the American Cancer Society. Almost 150,000 new cases of colorectal cancer are diagnosed and approximately 50,000 people die from the disease every year."